Literature DB >> 27769906

Transthyretin Cardiac Amyloidosis in Older Americans.

Danielle L Brunjes1, Adam Castano1, Autumn Clemons1, Jonah Rubin1, Mathew S Maurer2.   

Abstract

Wild-type transthyretin cardiac amyloidosis (ATTRwt), formerly called senile cardiac amyloidosis (SCA), is almost exclusively a disorder of older adults. As the population ages, the diagnosis of ATTRwt will increase, making it the most common form of cardiac amyloidosis. An important precondition to reduce underdiagnosis and misdiagnosis is to maintain a high index of suspicion for cardiac amyloidosis. Several clues can be gleaned from the clinical history, physical exam, electrocardiography, and noninvasive imaging techniques. Nuclear scintigraphy agents using 99mTc-phosphate derivatives combined with assessment for monoclonal proteins are eliminating the need for tissue confirmation in ATTR. Morbidity and mortality from ATTRwt cardiac amyloid is high and the emergence of numerous therapies based on a biologic understanding of the pathophysiology of this condition, including drugs to inhibit the synthesis of TTR, stabilize TTR, and degrade or extract amyloid, provides new hope for those afflicted. This review briefly covers the epidemiology, pathophysiology, and clinical manifestations, as well as diagnostic strategies and treatment, of ATTR in older adults. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Transthyretin cardiac amyloidosis; diagnostic strategies; geriatric heart failure

Mesh:

Year:  2016        PMID: 27769906      PMCID: PMC5127719          DOI: 10.1016/j.cardfail.2016.10.008

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  55 in total

1.  Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.

Authors:  Candida Cristina Quarta; Scott D Solomon; Imran Uraizee; Jenna Kruger; Simone Longhi; Marinella Ferlito; Christian Gagliardi; Agnese Milandri; Claudio Rapezzi; Rodney H Falk
Journal:  Circulation       Date:  2014-02-21       Impact factor: 29.690

2.  Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System.

Authors:  Martha Grogan; Christopher G Scott; Robert A Kyle; Steven R Zeldenrust; Morie A Gertz; Grace Lin; Kyle W Klarich; Wayne L Miller; Joseph J Maleszewski; Angela Dispenzieri
Journal:  J Am Coll Cardiol       Date:  2016-09-06       Impact factor: 24.094

3.  Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish.

Authors:  Shikha Mishra; Jian Guan; Eva Plovie; David C Seldin; Lawreen H Connors; Giampaolo Merlini; Rodney H Falk; Calum A MacRae; Ronglih Liao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-26       Impact factor: 4.733

4.  Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center.

Authors:  Raymond C Givens; Chris Russo; Philip Green; Mathew S Maurer
Journal:  Aging health       Date:  2013-04-01

5.  Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts.

Authors:  R Liao; M Jain; P Teller; L H Connors; S Ngoy; M Skinner; R H Falk; C S Apstein
Journal:  Circulation       Date:  2001-10-02       Impact factor: 29.690

6.  Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis.

Authors:  David F Hutt; Anne-Marie Quigley; Joanne Page; Margaret L Hall; Maria Burniston; Dorothea Gopaul; Thirusha Lane; Carol J Whelan; Helen J Lachmann; Julian D Gillmore; Philip N Hawkins; Ashutosh D Wechalekar
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-06-16       Impact factor: 6.875

7.  Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis.

Authors:  A Pollak; R H Falk
Journal:  Chest       Date:  1993-08       Impact factor: 9.410

Review 8.  Transthyretin (TTR) cardiac amyloidosis.

Authors:  Frederick L Ruberg; John L Berk
Journal:  Circulation       Date:  2012-09-04       Impact factor: 29.690

9.  Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models.

Authors:  Isabel Cardoso; Diana Martins; Tania Ribeiro; Giampaolo Merlini; Maria João Saraiva
Journal:  J Transl Med       Date:  2010-07-30       Impact factor: 5.531

10.  Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis.

Authors:  Per Westermark; Gunilla T Westermark; Ole B Suhr; Svante Berg
Journal:  Ups J Med Sci       Date:  2014-03-12       Impact factor: 2.384

View more
  13 in total

1.  Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.

Authors:  Mark Miller; Arindom Pal; Wabel Albusairi; Hyun Joo; Beverly Pappas; Md Tariqul Haque Tuhin; Dengpan Liang; Raghavendra Jampala; Fang Liu; Jared Khan; Marjon Faaij; Miki Park; William Chan; Isabella Graef; Robert Zamboni; Neil Kumar; Jonathan Fox; Uma Sinha; Mamoun Alhamadsheh
Journal:  J Med Chem       Date:  2018-08-22       Impact factor: 7.446

2.  Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).

Authors:  Pooja Phull; Vaishali Sanchorawala; Lawreen H Connors; Gheorghe Doros; Frederick L Ruberg; John L Berk; Shayna Sarosiek
Journal:  Amyloid       Date:  2018-02-09       Impact factor: 7.141

Review 3.  Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.

Authors:  Mathew S Maurer; Sabahat Bokhari; Thibaud Damy; Sharmila Dorbala; Brian M Drachman; Marianna Fontana; Martha Grogan; Arnt V Kristen; Isabelle Lousada; Jose Nativi-Nicolau; Candida Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Ronald Witteles; Giampaolo Merlini
Journal:  Circ Heart Fail       Date:  2019-09-04       Impact factor: 8.790

Review 4.  Assessment and Management of Older Patients With Transthyretin Amyloidosis Cardiomyopathy: Geriatric Cardiology, Frailty Assessment and Beyond.

Authors:  Biobelemoye Irabor; Jacqueline M McMillan; Nowell M Fine
Journal:  Front Cardiovasc Med       Date:  2022-05-17

5.  Transthyretin Cardiac Amyloidosis in Older Adults: Optimizing Cardiac Imaging to the Corresponding Diagnostic and Management Goal.

Authors:  Adam Castaño; Daniel K Manson; Mathew S Maurer; Sabahat Bokhari
Journal:  Curr Cardiovasc Risk Rep       Date:  2017-04-25

6.  Musculoskeletal pathology as an early warning sign of systemic amyloidosis: a systematic review of amyloid deposition and orthopedic surgery.

Authors:  Austin E Wininger; Brian M Phelps; Jessica T Le; Joshua D Harris; Barry H Trachtenberg; Shari R Liberman
Journal:  BMC Musculoskelet Disord       Date:  2021-01-08       Impact factor: 2.362

7.  Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups.

Authors:  David Rintell; Dena Heath; Florencia Braga Mendendez; Elizabeth Cross; Theodore Cross; Vincent Knobel; Bruno Gagnon; Cameron Turtle; Alan Cohen; Edward Kalmykov; Jonathan Fox
Journal:  Orphanet J Rare Dis       Date:  2021-02-08       Impact factor: 4.123

8.  Discovery of Bispecific Antagonists of Retinol Binding Protein 4 That Stabilize Transthyretin Tetramers: Scaffolding Hopping, Optimization, and Preclinical Pharmacological Evaluation as a Potential Therapy for Two Common Age-Related Comorbidities.

Authors:  Christopher L Cioffi; Parthasarathy Muthuraman; Arun Raja; Andras Varadi; Boglarka Racz; Konstantin Petrukhin
Journal:  J Med Chem       Date:  2020-09-17       Impact factor: 8.039

9.  Rapid decline in ejection fraction and persistent elevation of troponin associated with cardiac amyloidosis.

Authors:  Temidayo Abe; Eric Y Chang; Gabrielle De Allie; Taiwo Ajose; Chukwuemeka Nwokike; Nicolas Bakinde
Journal:  SAGE Open Med Case Rep       Date:  2020-05-20

10.  Diagnosis of Amyloidosis: A Survey of Current Awareness and Clinical Challenges Among Cardiologists in Switzerland.

Authors:  Dennis Mircsof
Journal:  Cardiol Ther       Date:  2020-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.